Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
NCT ID: NCT00099801
Last Updated: 2017-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
2005-01-31
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
NCT00099749
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant
NCT00099736
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
NCT00239902
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
NCT00239876
Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
NCT00239811
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FTY720
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female age 18 to 65 years
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Novartis Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis
Role: STUDY_DIRECTOR
Novartis
References
Explore related publications, articles, or registry entries linked to this study.
Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch Ophthalmol. 2008 Jan;126(1):140-1. doi: 10.1001/archophthalmol.2007.23. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFTY720A2307
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.